Login to Your Account



Pharma: Clinic Roundup


Thursday, June 13, 2013
• Grupo Ferrer Internacional SA, of Barcelona, Spain, completed a global Phase III trial evaluating ozenoxacin formulated as a topical treatment in adult and in pediatric patients 2 years and older with impetigo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription